A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.

Date publication

janvier 2021

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe , Dr BEN ABDELGHANI Meher , Pr PETIT Thierry , Pr PIVOT Xavier , Dr SCHOTT Roland , Dr DEMARCHI Martin , Dr COLIAT Pierre

Tous les auteurs :
Demarchi M, Coliat P, Barthelemy P, Schott R, BenAbdelghani M, Kim M, Hii JCS, Feyaerts P, Ang FRX, Derde MP, Deforce F, Petit T, Schwabe C, Wynne C, Park LS, Pivot X

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34555031

Résumé

This first-in-human study was designed to evaluate the pharmacokinetic (PK) equivalence between HD204 and the European Union (EU)-sourced bevacizumab, between HD204 and the United States of America (US)-sourced bevacizumab, and between EU-sourced and US-sourced bevacizumab (NCT03390673).

Référence

PLoS One. 2021 ;16(9):e0248222